Maria Vertzoni

List of Publications by Year
in descending order

89 papers	4,185 citations	147801 31 h-index	114465 63 g-index
93 all docs	93 docs citations	93 times ranked	2497 citing authors

#	Article	IF	Citations
1	Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, 413-417.	4.3	327
2	In vitro models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences, 2014, 57, 342-366.	4.0	297
3	The mechanisms of pharmacokinetic food-drug interactions â€“ A perspective from the UNGAP group. European Journal of Pharmaceutical Sciences, 2019, 134, 31-59.	4.0	224
4	Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspectsâ€. Journal of Pharmacy and Pharmacology, 2010, 56, 453-462.	2.4	206
5	Precipitation in and Supersaturation of Contents of the Upper Small Intestine After Administration of Two Weak Bases to Fasted Adults. Pharmaceutical Research, 2011, 28, 3145-3158.	3.5	179
6	In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 173-182.	4.3	152
7	Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. European Journal of Pharmaceutical Sciences, 2019, 134, 153-175.	4.0	146
8	Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 107-114.	4.3	144
9	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences, 2021, 162, 105812.	4.0	137
10	Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. European Journal of Pharmaceutical Sciences, 2009, 37, 434-441.	4.0	120
11	Characterization of the Contents of Ascending Colon to Which Drugs are Exposed After Oral Administration to Healthy Adults. Pharmaceutical Research, 2009, 26, 2141-2151.	3.5	118
12	Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: Case studies with fenofibrate. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 427-437.	4.3	111
13	Biorelevant Media to Simulate Fluids in the Ascending Colon of Humans and Their Usefulness in Predicting Intracolonic Drug Solubility. Pharmaceutical Research, 2010, 27, 2187-2196.	3.5	95
14	Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 257-264.	4.3	93
15	In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 70-83.	4.3	91
16	Estimation of Intragastric Solubility of Drugs: In What Medium?. Pharmaceutical Research, 2007, 24, 909-917.	3.5	88
17	Drug Supersaturation in Simulated Human Intestinal Fluids Representing Different Nutritional States. Journal of Pharmaceutical Sciences, 2010, 99, 4525-4534.	3.3	88
18	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Advanced Drug Delivery Reviews, 2021, 171, 289-331.	13.7	84

#	Article	IF	Citations
19	An In Vitro Methodology for Forecasting Luminal Concentrations and Precipitation of Highly Permeable Lipophilic Weak Bases in the Fasted Upper Small Intestine. Pharmaceutical Research, 2012, 29, 3486-3498.	3.5	79
20	Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 127-138.	4.3	69
21	Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug â€“ Drug Interaction Studies. Pharmaceutical Research, 2016, 33, 1399-1412.	3.5	64
22	Gastrointestinal transfer: In vivo evaluation and implementation in in vitro and in silico predictive tools. European Journal of Pharmaceutical Sciences, 2014, 63, 233-242.	4.0	63
23	Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers. Molecular Pharmaceutics, 2012, 9, 1189-1198.	4.6	60
24	An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation. European Journal of Pharmaceutical Sciences, 2016, 82, 106-114.	4.0	60
25	Insights into Intermediate Phases of Human Intestinal Fluids Visualized by Atomic Force Microscopy and Cryo-Transmission Electron Microscopy ex Vivo. Molecular Pharmaceutics, 2012, 9, 237-247.	4.6	59
26	Characterization of Contents of Distal Ileum and Cecum to Which Drugs/Drug Products are Exposed During Bioavailability/Bioequivalence Studies in Healthy Adults. Pharmaceutical Research, 2015, 32, 3338-3349.	3.5	59
27	Mechanistic investigation of the negative food effect of modified release zolpidem. European Journal of Pharmaceutical Sciences, 2017, 102, 284-298.	4.0	57
28	The impact of food intake on the luminal environment and performance of oral drug products with a view toin vitroandin silicosimulations: a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 557-580.	2.4	51
29	Solubilization and quantification of lycopene in aqueous media in the form of cyclodextrin binary systems. International Journal of Pharmaceutics, 2006, 309, 115-122.	5.2	40
30	Degradation kinetics of metronidazole and olsalazine by bacteria in ascending colon and in feces of healthy adults. International Journal of Pharmaceutics, 2011, 413, 81-86.	5.2	40
31	Determination of intralumenal individual bile acids by HPLC with charged aerosol detection. Journal of Lipid Research, 2008, 49, 2690-2695.	4.2	39
32	Characterization of the Ascending Colon Fluids in Ulcerative Colitis. Pharmaceutical Research, 2010, 27, 1620-1626.	3.5	30
33	The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration. AAPS Journal, 2018, 20, 71.	4.4	30
34	In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT. International Journal of Pharmaceutics, 2016, 515, 352-358.	5.2	29
35	Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products â€“ a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 603-642.	2.4	29
36	Nasal powders of quercetin-Î²-cyclodextrin derivatives complexes with mannitol/lecithin microparticles for Nose-to-Brain delivery: In vitro and ex vivo evaluation. International Journal of Pharmaceutics, 2021, 607, 121016.	5.2	27

#	Article	IF	Citations
37	Evaluation of the Impact of Excipients and an Albendazole Salt on Albendazole Concentrations in Upper Small Intestine Using an InÂVitro Biorelevant Gastrointestinal Transfer (BioGIT) System. Journal of Pharmaceutical Sciences, 2016, 105, 2896-2903.	3.3	26
38	Evaluation of Dissolution in the Lower Intestine and Its Impact on the Absorption Process of High Dose Low Solubility Drugs. Molecular Pharmaceutics, 2017, 14, 4181-4191.	4.6	26
39	Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug, in dogs. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 338-345.	4.3	24
40	In vitro vs. canine data for assessing early exposure of doxazosin base and its mesylate salt. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 402-409.	4.3	24
41	Identification of key factors affecting the oral absorption of salts of lipophilic weak acids: a case example. Journal of Pharmacy and Pharmacology, 2014, 67, 56-67.	2.4	24
42	Comparison of simulated cumulative drug versus time data sets with indices. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56, 421-428.	4.3	21
43	Physiologically Based Absorption Modeling of Salts of Weak Bases Based on Data in Hypochlorhydric and Achlorhydric Biorelevant Media. AAPS PharmSciTech, 2018, 19, 2851-2858.	3.3	21
44	Physiological Considerations and In Vitro Strategies for Evaluating the Influence of Food on Drug Release from Extended-Release Formulations. AAPS PharmSciTech, 2018, 19, 2885-2897.	3.3	20
45	Measuring pH and Buffer Capacity in Fluids Aspirated from the Fasted Upper Gastrointestinal Tract of Healthy Adults. Pharmaceutical Research, 2020, 37, 42.	3.5	20
46	Effectiveness of supersaturation promoting excipients on albendazole concentrations in upper gastrointestinal lumen of fasted healthy adults. European Journal of Pharmaceutical Sciences, 2016, 91, 11-19.	4.0	19
47	The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen: Data in biorelevant media and in human aspirates. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 115, 94-101.	4.3	19
48	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. European Journal of Pharmaceutical Sciences, 2020, 155, 105517.	4.0	18
49	Characteristics of contents in the upper gastrointestinal lumen after a standard high-calorie high-fat meal and implications for the in vitro drug product performance testing conditions. European Journal of Pharmaceutical Sciences, 2020, 155, 105535.	4.0	18
50	Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapadâ“‡ membrane and in vivo absorption. European Journal of Pharmaceutical Sciences, 2020, 152, 105452.	4.0	17
51	Exploring precipitation inhibitors to improve in vivo absorption of cinnarizine from supersaturated lipid-based drug delivery systems. European Journal of Pharmaceutical Sciences, 2021, 159, 105691.	4.0	16
52	A LC-MS-MS Method for Determination of Low Doxazosin Concentrations in Plasma after Oral Administration to Dogs. Journal of Chromatographic Science, 2010, 48, 114-119.	1.4	15
53	Two-Stage Single-Compartment Models to Evaluate Dissolution in the Lower Intestine. Journal of Pharmaceutical Sciences, 2015, 104, 2986-2997.	3.3	15
54	Evaluating the clinical importance of bacterial degradation of therapeutic agents in the lower intestine of adults using adult fecal material. European Journal of Pharmaceutical Sciences, 2018, 125, 142-150.	4.0	14

#	Article	IF	Citations
55	Development and evaluation of a biorelevant medium simulating porcine gastrointestinal fluids. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 116-126.	4.3	14
56	Supersaturated lipid-based drug delivery systems â€“ exploring impact of lipid composition type and drug properties on supersaturability and physical stability. Drug Development and Industrial Pharmacy, 2020, 46, 356-364.	2.0	14
57	The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo - in vitro investigation.. European Journal of Pharmaceutical Sciences, 2020, 151, 105377.	4.0	14
58	On the usefulness of compendial setups and tiny-TIM system in evaluating the in vivo performance of oral drug products with various release profiles in the fasted state: Case example sodium salt of A6197. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 149, 154-162.	4.3	13
59	Disposition of two highly permeable drugs in the upper gastrointestinal lumen of healthy adults after a standard high-calorie, high-fat meal. European Journal of Pharmaceutical Sciences, 2020, 149, 105351.	4.0	13
60	In Vitro and Ex Vivo Investigation of the Impact of Luminal Lipid Phases on Passive Permeability of Lipophilic Small Molecules Using PAMPA. Pharmaceutical Research, 2013, 30, 3145-3153.	3.5	12
61	Ex vivo evaluation of degradation rates of metronidazole and olsalazine in distal ileum and in cecum: The impact of prandial state. International Journal of Pharmaceutics, 2017, 534, 237-241.	5.2	11
62	On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food. AAPS Journal, 2020, 22, 6.	4.4	11
63	Controlled Release from Solid Pharmaceutical Formulations of two Nalkanoyl-4-methoxybicyclo[4.2.0]octa-1,3,5-trien-7-ethanamines with Melatoninergic Activity. Letters in Drug Design and Discovery, 2015, 12, 259-262.	0.7	10
64	Unravelling the ultrastructure of ascending colon fluids from patients with ulcerative colitis by cryogenic transmission electron microscopy. Journal of Pharmacy and Pharmacology, 2013, 65, 1482-1487.	2.4	9
65	Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions. AAPS Journal, 2020, 22, 126.	4.4	9
66	Characteristics of Contents of Lower intestine in the 65â€“74ÂYears of Age Range Could Impact the Performance of Safe and Efficacious Modified Release Products. Journal of Pharmaceutical Sciences, 2021, 110, 251-258.	3.3	9
67	On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state. European Journal of Pharmaceutical Sciences, 2022, 168, 106034.	4.0	9
68	The mechanism of solifenacin release from a pH-responsive ion-complex oral suspension in the fasted upper gastrointestinal lumen. European Journal of Pharmaceutical Sciences, 2020, 142, 105107.	4.0	8
69	Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration. Journal of Pharmacy and Pharmacology, 2021, 73, 437-446.	2.4	8
70	Combining species specific in vitro & in silico models to predict in vivo food effect in a preclinical stage â€“ case study of Venetoclax. European Journal of Pharmaceutical Sciences, 2021, 162, 105840.	4.0	8
71	In-vitro evaluation of performance of solid immediate release dosage forms of weak bases in upper gastrointestinal lumen: experience with miconazole and clopidogrel salts. Journal of Pharmacy and Pharmacology, 2016, 68, 579-587.	2.4	8
72	In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance. AAPS Journal, 2018, 20, 100.	4.4	7

#	Article	IF	Citations
73	The Impact of Handling and Storage of Human Fecal Material on Bacterial Activity. Journal of Pharmaceutical Sciences, 2016, 105, 3458-3461.	3.3	6
74	Factors Affecting Successful Extrapolation of Ibuprofen Exposure from Adults to Pediatric Populations After Oral Administration of a Pediatric Aqueous Suspension. AAPS Journal, 2020, 22, 146.	4.4	6
75	Toward simplified oral lipid-based drug delivery using mono-/di-glycerides as single component excipients. Drug Development and Industrial Pharmacy, 2020, 46, 2051-2060.	2.0	6
76	Mapping the intermediate digestion phases of human healthy intestinal contents from distal ileum and caecum at fasted and fed state conditions. Journal of Pharmacy and Pharmacology, 2017, 69, 265-273.	2.4	5
77	Dissolution testing of modified release products with biorelevant media: An OrBiTo ring study using the USP apparatus III and IV. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 40-49.	4.3	5
78	In Vivo Performance of Innovative Polyelectrolyte Matrices for Hot Melt Extrusion of Amorphous Drug Systems. Molecular Pharmaceutics, 2020, 17, 3053-3061.	4.6	4
79	Exploring the impact of Crohnâ€™s disease on the intragastric environment of fasted adults. ADMET and DMPK, 2020, 8, 122.	2.1	4
80	In Vitro Simulation of the Environment in the Upper Gastrointestinal Lumen After Drug Administration in the Fed State Using the TIM-1 System and Comparison With Luminal Data in Adults. Journal of Pharmaceutical Sciences, 2022, 111, 197-205.	3.3	4
81	1H NMR Monitoring of the Canine Metabolic Profile after Oral Administration of Xenobiotics Using Multivariate Statistics. Molecular Pharmaceutics, 2007, 4, 258-268.	4.6	3
82	Toward the establishment of a standardized pre-clinical porcine model to predict food effects â€“ Case studies on fenofibrate and paracetamol. International Journal of Pharmaceutics: X, 2019, 1, 100017.	1.6	3
83	Usefulness of Optimized Human Fecal Material in Simulating the Bacterial Degradation of Sulindac and Sulfinpyrazone in the Lower Intestine. Molecular Pharmaceutics, 2022, 19, 2542-2548.	4.6	3
84	Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling. Journal of Pharmaceutical Sciences, 2021, 110, 3874-3888.	3.3	2
85	Performance Evaluation of Montelukast Pediatric Formulations: Part II â€” a PBPK Modelling Approach. AAPS Journal, 2022, 24, 27.	4.4	2
86	5. Estimation of intraluminal drug solubility. , 2019, , 133-148.		1
87	Evaluating pediatric and adult simulated fluids solubility: Abraham solvation parameters and multivariate analysis. Pharmaceutical Research, 2021, 38, 1889.	3.5	1
88	Performance Evaluation of Montelukast Pediatric Formulations: Part Iâ€”Age-Related In Vitro Conditions. AAPS Journal, 2022, 24, 26.	4.4	1
89	Understanding the Impact of Age-Related Changes in Pediatric GI Solubility by Multivariate Data Analysis. Pharmaceutics, 2022, 14, 356.	4.5	0